Resumen

Primary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric oxide \[FeNO\]), and concomitant treatments for asthma. Secondary Objectives: The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT for asthma (eg, most commonly used regimens, reason for initiation of new asthma treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching) * To assess the effectiveness of DUPIXENT in asthma patients in a real world setting (lung function improvement, exacerbation rate, asthma control) * To assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects of treatment in comorbid conditions in asthma patients treated with Dupixent * To collect data on HealthCare Resource Utilization (HCRU) * To collect safety data on study participants in the real-world setting.

Descripción detallada

Each patient will be followed for up to 36 months.

Elegibilidad

Edad mínima: 12 YearsSexo: ALL

Criterios de inclusión

Male or female, 12 years or older
Initiating treatment with Dupixent for asthma according to the country-specific prescribing information
Willing and able to comply with the required clinic visits, study procedures and assessments.
Provided signed informed consent

Criterios de exclusión

Patients who have a contraindication to Dupixent according to the country-specific prescribing information
Treatment with Dupixent within 6 months before the baseline visit. Note: for patients who have been treated previously with DUPIXENT a washout period of 6 months is required before Visit 1.
Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments
Patients currently participating in any interventional clinical trial which modifies patient care.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ubicaciones

Investigational Site Number : 0320005

La Plata, Buenos Aires, Argentina

Investigational Site Number : 0320006

Villa Rosa, Buenos Aires, Argentina

Investigational Site Number : 0320001

Ciudad Autonoma Bs As, Argentina

Investigational Site Number : 0320008

Ciudad Autonoma Buenos Aires, Argentina

Investigational Site Number : 0320009

San Miguel de Tucumán, Argentina

Investigational Site Number : 0320004

Santa Fe, Argentina

PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting